Discontinuation of Ibrutinib Is Common in Older Patients With CLL, Study Finds

Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.

Related Keywords

Pharmacyclics Janssen , ,Image Credit ,Cancer Medicine ,Cll ,Chronic Lymphocytic Leukemia ,Ibrutinib ,Discontinuation ,